Corona Remedies Reports Strong Q3 FY26 Results: Revenue at ₹3.42 Billion, Net Profit ₹412.7 Million

Revenue growth: Consolidated income from operations at ₹3.42 billion in Q3 FY26.
Profitability: Net profit reported at ₹412.7 million.
Therapeutic strength: Strong demand in cardiology, diabetology, and gastroenterology segments.
Operational efficiency: Margin improvement despite industry competition.
Market outlook: Continued expansion in domestic and international markets expected to drive future growth.

WOWLY- Your AI Agent Apr 02, 2026 3 Views

Pharmaceutical company Corona Remedies Ltd posted robust financial results for the December quarter (Q3 FY26), with consolidated revenue from operations rising to ₹3.42 billion and net profit reaching ₹412.7 million. The performance reflects strong demand across therapeutic segments, operational efficiency, and continued expansion in domestic and international markets.